Introduction 39
Monoclonal antibodies (mAbs) are indispensable molecules for therapeutic, diagnostic as well 40 as for biotechnological applications. As one of the main drivers of the pharmaceutical 41 industry, mAbs are the highest selling class of biological entities with current and predicted 42 market growth rates, substantially exceeding those of the overall sector (1, 2). Their 43 outstanding clinical efficacy in conjunction with several dozen marketed antibodies and 44 hundreds of mAbs in clinical development is corroborating their paramount therapeutic 45 potential (2-6). This is exemplified by the fact that five recombinant antibody therapeutics 46 were granted first marketing approvals in 2014, as of October 2014. In addition, seven entities 47 are currently undergoing a first regulatory review in the US or Europe (7). However, for 48 specific applications, such as in vivo imaging, the efficacy of classical antibody molecules 49 might be impaired by reason of their large hetero-tetrameric structure (Fig. 1, left) . Slow 50 blood clearance, restricted tumor penetration as well as non-specific uptake by healthy tissues 51 might pose problems for distinct applications (8-12) To address these issues and consequently 52 to substantially enlarge the repertoire of biologic therapeutics and diagnostics in order to 53 ultimately select the right molecule for an individual application, next-generation antibodies, 54 such as antibody-drug conjugates (13, 14) or immunocytokines (15), antibody fragments (16) 55 and scaffold proteins (17-19) were generated. Related to this, antigen-binding sites were 56 introduced into the Fc-fragment of human IgG, significantly reducing the complex nature of a 57 full-length antibody, as reviewed by Dimitrov and colleagues (20) . In a very elegant 58 approach, described by Rüker and co-workers, antigen-binding sites were engineered into the 59 C-terminal tip of CH3, while retaining functionality of the Fc-part, e.g. long serum half-life 60 and antibody-dependent cellular cytotoxicity (21) . 61
In addition to engineered antibody-derivatives, the immune systems of camelids and sharks 62 comprises non-conventional heavy chain only antibody molecules (22, 23), where antigen 63 binding is mediated solely by one single domain, referred to as VHH and vNAR, respectively. 64
In general, those domains exhibit high specificities for a cognate antigen, high physico-65 chemical stability as well as a small size and are thus considered as promising candidates for 66 biomedical development. homo-dimer in which each chain consists of five constant domains, followed by a variable 168 domain (vNAR, IgNAR V), solely facilitating antigen binding (Fig 1, right) (47). The IgNAR 169 V domain displays several unique features, clearly distinguishing it from camelid VHH 170 domains. Due to a deletion in the framework2-CDR2-region, the β-sandwich fold only 171 consists of 8 instead of 10 β-strands, making the vNAR domain the smallest antigen binding 172 antibody-like domain in the animal kingdom known to date, with a molecular mass of 173 approximately 12 kDa (48, 49). Consequently IgNAR V domains only have two 174 complementarity determining regions CDR1 and CDR3 (Fig. 1, right) . However, at the 175 CDR2 truncation site, the remaining surface exposed loop forms a 'belt-like' structure and it 176 was shown that after antigen-contact, high rates of somatic mutation also occur in this loop 177 and in a loop which corresponds to HV4 in T-cell receptors, to which vNAR domains show 178 structural similarity. Hence, these regions have been termed HV2 and HV4, respectively (50). Notwithstanding, it is known that even humanized and fully human antibodies such as 218
Adalimumab
® are able to significantly induce immunogenicity, essentially demonstrating that 219 it needs to be scrutinized for each individual therapeutic candidate how these proteins will 220 behave with regard to adverse events when injected to patients in the scope of clinical trials 221 (80-84). 222
223

Human antibody variable domains 224
Human domain antibodies are the smallest known fragments from variable domains of 225 conventional antibodies with retained antigen-binding function and sizes ranging between 11-226 15 kDa. This antibody type includes antibody heavy (VH dAb) or light chain (VL dAb) 227 variable fragments and comprises three CDRs that mediate specific antigen-interaction (25). 228
In their structure, human dAbs closely resemble the architecture of paired variable fragments 229 in conventional antibodies ( Fig. 1 top) (25, 85) . In contrast to the naturally evolved equivalent 230 in camelids and sharks, early studies revealed that single human VH domains are prone to 231 aggregation and exhibit poor solubility, which is caused by solvent exposure of hydrophobic 232 patches in the absence of an interacting VL domain (86). 233
The unfavorable properties were tackled in a variety of mutational approaches and initial 234 attempts aimed at the transfer of VHH key elements that attributed aggregation-resistance and 235 good solubility to camelid VHHs (85). A process was established, named "camelization", in 236 which residues of the VL-interface were substituted with hydrophilic residues that are 237 conserved in VHHs (G44E/L45R/W47G) (86). Furthermore, it also became clear that 238 composition and length of the CDRs are determinants of aggregation-propensity and a 239 positive effect on solubility of VH dAbs was shown by the extension of the CDR3 length (25, 240 86, 87). All these studies pointed out residues of the dAb framework and the CDRs as critical 241 constituents for good biophysical properties and provided guidance for the engineering of 242 scaffolds for library applications. 243
Nowadays, convenient generation of human dAbs with desired properties and specificities has 244 been achieved using molecular evolution approaches (e.g. phage display) and repertoires of 245 
gov). 274
Although it has been proposed that dAbs have a low immunogenicity, a novel type of pre-275 existing anti-drug antibody was recently discovered during the development of anti-TNFR1 276 GSK1995057 (100). Herein, autoantibody-binding to framework sequences of the fully 277 human VH dAbs triggered activation of TNFR1 in in vitro assays and in some drug-naïve 278 subjects the release of cytokines in vivo (100). GSK2374697 was developed for treatment of 279 
Engineered monomeric human IgG1 CH2 and CH3 as a scaffold 306
Another class of conventional antibody derived single domains has recently been introduced 307 for scaffold application including engineered CH2 and CH3 domains (26). The most13 remarkable feature of engineered domains is their proposed long half-life due to functional 309 FcRn-binding. However engineered CH2 domains seem to have a high aggregation tendency 310 (110, 111). The antiparallel β-strand structure of CH2 domains is similar to that of human VH 311 domains comprising three loops (BC, DE and FG) in that the BC and FG loops at the N-312 terminal tip can be used for diversification (112). A CH2 variant was engineered (m01s) by 313 the incorporation of an additional intra-domain disulfide-bridge between A and G strands and 314 the elimination of several N-terminal residues. In contrast to the wild-type CH2, the m01s 315 variant exhibited pronounced thermal stability, good expression yield and high solubility 316 (113). In vivo mice studies with injected m01s revealed a longer half-life due to FcRn-317 interaction, compared to scaffolds of similar size that do not interact with FcRn (114) . 318
Furthermore, m01s was used for phage library construction by grafting human VH CDR3 319 diversities into the loop FG and mutagenesis of the BC and DE loops. One variant was 320 isolated (m2a1) that showed selective binding to sp62 from the HIV-1 membrane proximal 321
external region (MPER) and functional FcRn-binding (110). 322
In addition, a monomeric soluble CH3 domain (mCH3) was developed recently (115). A 323 structure guided mutagenesis approach led to the identification of four residues in the CH3 324 dimerization interface that were shown to be crucial for the generation of monomeric CH3 325 domains. Furthermore, the thermal stability was increased by incorporation of a disulfide 326 bridge (from Tm= 40,6 °C to Tm=76 °C). Nevertheless, mCH3 was able to bind FcRn in a 327 pH-dependent manner. Anyhow, the measured affinity was lower compared to wild type Fc 328 (KD 940 nM versus 126 nM). This is attributed to the lacking CH2 domain, as residues of 329 CH2 and CH3 in IgG1 together are responsible for FcRn interaction. In this proof of concept 330 study the HIV-1 neutralizing dAb m36.4 was generated as a fusion protein with mCH3 331 
